Summary. This paper considers the problem of estimating the average controlled direct e ect ACDE of a treatment on an outcome, in the presence of unmeasured confounders between an intermediate variable and the outcome. Such confounders render the direct e ect unidenti able even in cases where the total e ect is unconfounded hence identi able. Kaufman et al. 2005 applied a linear programming software to nd the minimum and maximum possible values of the ACDE for speci c numerical data. In this paper, we apply the symbolic Balke-Pearl 1997 linear programming method to derive closed-form formulas for the upper and lower bounds on the ACDE under various assumptions of monotonicity. These universal bounds enable clinical experimenters to assess the direct e ect of treatment from observed data with minimum computational e ort, and they further shed light on the sign of the direct e ect and the accuracy of the assessments.
Introduction
Estimation of the direct e ect of a treatment on an outcome is a central concern in epidemiological and clinical research Buyse and Molenberghs, 1998 Kaufman et al., 2005 Petersen et al., 2006 Robins and Greenland, 1992 Rubin, 2004 Taylor et al., 2005 Wang and Taylor, 2002 . Pearl 2001 gave a formal de nition of the total e ect decomposition into direct and indirect e ects, and distinguished between the controlled direct e ect and the natural direct e ect, the former obtains when intermediate variables are held constant at speci c values. Kaufman et al. 2005 considered the problem of estimating the average controlled direct e ect ACDE of a treatment on an outcome, in the presence of unmeasured confounders between an intermediate variable and the outcome. Such confounders render the direct e ect unidenti able even in cases where the total e ect is unconfounded hence identi able. Kaufman et al. 2005 applied a linear programming software to nd the minimum and maximum possible values of the ACDE for speci c numerical data. They further proposed the midpoint b e t ween the minimum and maximum values as an estimator of the ACDE. However, they did not provide exact formulas of the bounds on the ACDE.
In this paper, we apply the symbolic Balke-Pearl linear programming method Balke, 1995 Balke and Pearl, 1997 to derive closed-form formul a s o f t h e upper and lower bounds on the ACDE under various assumptions of monotonicity. In contrast to the numerical method of Kaufman et al. 2005 , these symbolic formulas enable clinical experimenters to assess the direct e ect of a treatment on an outcome from observed data with minimum computational e ort, and they further shed lights on the accuracy of the assessment. In addition, we d e r i v e bounds on the ACDE when covariate information is available. Moreover, we p r o vide a formal formula for the midpoint estimator chosen by Kaufman et al. 2005 , and propose a new strati ed midpoint estimator that is more accurate when covariate measurements are available. In addition to the binary case, we further propose bounds on the ACDE in the case where observed variables are multi-categorical. Finally, we illustrate our results through an empirical example in both binary and multi-categorical cases.
Bounding formulas 2.1 Problem description
To motivate our problem, we examine the data from the Lipid Research Clinics Coronary Primary Prevention Trial LRC-CPPT, shown in Table 1 LRT-CPPT group, 1984 Kaufman et al, 2005 . The purpose of this study is to evaluate the e cacy of the cholesterol lowering drug cholestyramine for the prevention of coronary heart disease CHD in 3806 hypercholesterolemia men. Our interest is to examine whether serum cholesterol level 1 year after initiation of cholestyramine was an adequate surrogate endpoint i.e., explanation for the outcome of CHD.
According to Freedman et al. 1992 , a goodsurrogate endpoint is one that explains a large proportion of the total e ect. A c o n ventional approach to validate a surrogate endpoint is to estimate the relative contributions of the direct and indirect e ects to the total e ect. However, if there exist unmeasured confounding factors, for example, if there exist unmeasured genetic or life style factors that a ect both cholesterol and CHD, estimating the direct e ect requires careful causal analysis. To model presence of unmeasured confounding, we consider the directed acyclic graph shown in Fig. 1 , where a treatment X, a n i n termediate Z and an outcome Y are binary variables taken values as x, z and y respectively x 2 fx 0 x 1 g, y 2 fy 0 y 1 g, z 2 fz 0 z 1 g, and U is a set of unmeasured variables, which is independent o f X. In this gure, the treatment i s a s s u m e d randomized, hence there is no confounder between X and Y , and the total e ect of X on Y is identi able. However, the set of unmeasured confounders U between Z and Y renders the direct e ect of X on Y unidenti able. In other words, it is impossible to estimate this direct e ect without making further assumptions. The central aim of this paper is to derive formulas of the bounds on the direct e ect of X on Y in this causal structure. Eqn 1 represents the average causal e ect of X on Y when the causal path through Z is blocked by holding Z xed at z 0 or z 1 . Note that Eqn 1 is di erent from the crude stratum-speci c risk di erence pry 1 jx 1 z pry 1 jx 0 z . The latter stands for the observed conditional risk di erence in stratum z in our example, the subgroup with cholesterol 280mg dl or cholesterol280mg dl, which represents the direct e ect of X on Y , plus the spurious correlation between X and Y through the path X ! Z U ! Y . On the other hand, Eqn 1 represents the direct e ect only, since the path X ! Z U ! Y had beenblocked by an intervention on Z . If the ACDE equals 0 in our example, then we can judge that cholesterol Z is a perfect surrogate endpoint f o r C H D Y , which suggests that lowering cholesterol level constitutes an adequate explanation for how the drug prevents the occurrence of CHD.
In order to derive bounds on the ACDE, we f o l l o w Kaufman et al. 2005 and de ne 64 potential response types. First, we consider X cholestyramine as a treatment a n d Z cholesterol as an outcome. Since X and Z are binary variables, there are four possible potential response types at the unit-level: 1 a subject whose cholesterol increases regardless of taking cholestyramine or placebo doomed, 2 a subject whose cholesterol decreases only by taking cholestyramine causative, 3 a subject whose cholesterol decreases only by not taking cholestyramine preventive, and 4 a subject whose cholesterol decreases regardless of taking cholestyramine or placebo immune Greenland and Robins, 1986 . We index these four types by a mapping variable r z = 1 2 3 4. Similarly, w h e n w e consider X cholestyramine as a treatment and Y CHD as an outcome with Z cholesterol xed to z 0 or z 1 , there still exist doomed, causative, preventive and immune potential response types. We denote these four types by a mapping variable r yjz 0 = 1 2 3 4 w h e n Z is xed to z 0 , and another mapping variable r yjz 1 = 1 2 3 4 when Z is xed to is fully characterized by fq ijk g, and we can rewrite Eqn 2 as
See Appendix A for a detail derivation. Kaufman et al. 2005 applied a linear program software package to nd the minimum and maximum possible values of the ACDE for speci c numerical data. However, they did not provide exact formulas for the ACDE. Balke 1995 and Balke and Pearl 1997 describe a computer program that takes symbolicdescription of linear programming problems and returns symbolic expressions for the desired bounds. In this paper, we apply this symbolic method to derive closed-form formulas for the ACDEs under three sets of assumptions. Details of this method are included in Appendix A.
No assumption case
When no assumption is made, there are 64 potential response types, while there are only 8 observed conditional probabilities pry zjx. Using the symbolic Balke-Pearl method Balke, 1995 Balke and Pearl, 1997 , the formulas for the tightest lower and upper bounds on the ACDEs, are given by pry 0 z jx 0 + p r y 1 z jx 1 1 ACDEz 1 pry 1 z jx 0 pry 0 z jx 1 3 for z 2 fz 1 z 0 g, which de nes the range within which the ACDE must lie.
It is remarkable that we get such a simple formula, consisting of only one additive expression in the lower bound and one additive expression in the upper bound.
To nd when the lower boundcoincides with the upper bound, we calculate their di erence and obtain prz 1 i jx 0 + prz 1 i jx 1 for ACDEz i z i 2 fz 1 z 0 g. Hence, in order to make the lower bound equal the upper bound, both prz 1 i jx 0 and prz 1 i jx 1 must be zero. This indicates that the upper boundcannot coincide with the lower boundin bothACDEz 0
and ACDEz 1 at the same time, because the probabilities in all the cells must be zero in order to achieve it. That is, the bounding interval never vanishes, regardless of the observations.
In addition, it should be noted that Eqn 3 provides a simple testable criterion for the existence of a direct e ect, that is, if pry 0 z jx 0 +p r y 1 z jx 1 1, then we are assured that ACDEz is positive, and if pry 1 z jx 0 + pry 0 z jx 1 1, ACDEz must benegative.
2.3 Monotonic assumption case Kaufman et al. 2005 made two assumptions regarding the potential response types: 1 monotonic assumption, which means no unit-level causal e ects of X on Z or of X on Y or of Z on Y can be negative, and 2 no-interaction assumption, which means that, for all units, the response of Y to change in X does not depend on the level at which we hold Z.
There are 18 potential response types that satisfy monotonic assumption, that is, fq i11 q i21 q i22 q i41 q i42 q i44 : i = 1 2 4g, and 12 potential response types that satisfy bothmonotonic and no-interaction assumptions, that is, fq i11 q i22 q i41 q i44 : i = 1 2 4g Kaufman and Kaufman, 2006 . By applying the Balke-Pearl method, we derive closed-form formulas for the tightest bounds on the ACDEs in the two cases. The following equations give the lower and upper boundsunder monotonic assumption: On the basis of the lower bounds of Eqns 4 and 5, we can judge whether there exist positive direct e ects under the monotonic assumption.
That is, if pry 0 z 1 jx 0 pry 0 z 1 jx 1 and or pry 1 z 0 jx 1 pry 1 z 0 jx 0 , then we are assured that there exist positive direct e ects.
Moreover, Eqns 4 and 5 provide a simple necessary test for the monotonic assumption. That is, if the monotonic assumption holds true, then the upper boundsshould be no less than zero, because the lower bounds are nonnegative. Thus, if the observed quantities are pry 0 jx 0 pry 0 z 1 jx 1 o r pry 1 jx 1 pry 1 z 0 jx 0 , then the upper bounds would be negative, which indicates that the monotonic assumption does not hold in this situation. Further, Eqn 6 provides a simple necessary test for both monotonicity and no-interaction assumptions. Since ACDEz m ust be nonnegative from the lower bounds of Eqn 6, then, if pry 1 jx 1 pry 1 jx 0 , the upper bounds would benegative, which indicates that at least one of the two assumptions is violated. One more thing to be mentioned is that, because the monotonic assumption and no-interaction assumption add some constraints on the potential response types, the bounds under monotonic assumption should not be wider than those under no assumption, and similarly, the bounds under both monotonic and no-interaction assumptions should not bewider than those under monotonic assumption.
Estimation accuracy
In section 2.2 and 2.3, we derive the estimators for the lower and upper bounds under three sets of assumptions. Another problem is the estimation accuracy of these estimators. For no assumption case, it is easy to obtain the exact variance for the lower and upper bounds. However, for the remaining two cases, it is very complicated to derive t h e v ariances for the lower bounds though it is easy to obtain the exact variances for the upper bounds. In Appendix B, we provide the variance estimators for the lower and upper bounds under the three cases. In addition, we evaluate the performance of the proposed variance estimators through simulation studies.
Strati ed ACDE
The analysis of section 2 applies to situations where all confounders between Z and Y are unmeasured. However, if some of these confounders are observed, this information is helpful in narrowing the bounds on direct e ects.
In this section, we consider the directed acyclic graph with the set of confounders U in Fig. 1 being divided These summarized bounds on direct e ects are not wider than the bounds derived in Section 2, a simple proof of which is provided in Appendix C.
We would like t o p o i n t o u t some practical requirements for the observed covariates S. First of all, S must be baseline covariates in order for the method to be valid. Moreover, we can divide such baseline covariates into the following three cases: a S is a confounder between Z and Y b S has an e ect on Z but not on Y c S has an e ect on Y but not on Z. If the measured covariates S satis es any of the three cases, then the summarized bounds of Eqn 9 should not bewider than those provided in Section 2.
4. Midpoint estimator Kaufman et al. 2005 proposed the midpoint between the minimum and maximum values as an estimator of the ACDE, which is given as mRDz = U B z + LBz 2 z2fz 0 z 1 g 10 where LBz a n d U B z are the linear programming minimum and maximum values for ACDEz derived from the observed probabilities using linear programming packages. With the derived formulas in Section 2, we can now present an exact formula of the midpoint estimator. For example, the midpoint estimator with no assumption is derived directly as mRDz = 1 2 fpry 0 z jx 0 + p r y 1 z jx 1 pry 1 z jx 0 pry 0 z jx 1 g 11 based on Eqn 3. The midpoint estimators for the remaining two cases can bederived in the same way. Thus, we can calculate the midpoint estimator from the observed data without using linear programming packages. where S is a set of observed baseline covariates discussed in Section 3.
The new strati ed midpoint estimator is superior to the midpoint e s t i m ator when some covariates are observed. To see this, we consider a hypothetical example when both monotonic and no-interaction assumptions hold true, and there is a binary observed covariate S . Table 2 shows the true proportion of 12 potential response types in each stratum, and Table 3 shows the observed conditional probabilities pry z jx s induced from Table 2 . Here, prs 1 is set to be 0.45. Then, according to Kaufman et al's method, the bounds on the direct e ect are 0.050, 0.175, and the midpoint estimate is 0.112. On the other hand, the boundsare 0:190 0:230 in stratum s 1 and 0:090 0:130 in stratum s 0 according to our formula 8. Then, we calculate the summarized lower and upper bounds according to our summarized formula 9, which a r e 0.135, 0.175, and the strati ed midpoint estimator according to formula 12, which is 0.155. Here, we can calculate the true strati ed ACDE from Table 2 , which is 0:220 in stratum s 1 and 0:120 in stratum s 0 . In addition, the true ACDE is 0:165 from Table 2 , which is included in both Kaufman et al's bounds and our bounds. However, it is seen that Kaufman et al's midpoint estimator is quite away from the true ACDE and outside our bounds, while the strati ed midpoint estimator is close to the true ACDE.
Extension to multi-categorical case
In the discussion above, we consider the ACDE when observed variables are binary. In this section, we consider the case where X , Y and Z are multicategorical variables. When the categorical treatment v ariable X is changed from x to x 0 , we de ne the ACDE as The proof is given in Appendix D. When X , Y and Z are binary variables, these bounds are consistent with Eqn 3. Kang and Tian 2006 provided a method to obtain the inequality constraint for causal e ects from nonexperimental data in the presence of unobserved variables. The above bounds can also be obtained by using their method.
Empirical example 6.1 Binary case
We illustrate our results through the example given in Section 2. Kaufman et al. 2005 collapsed the serum cholesterol values into two categories from 5 original categories, based on the data in Freedman et al. 1992 . We will discuss the ve categories in next subsection.
Because treatment X is randomized, the total e ect of X on Y c a n b e u nbiased estimated by the risk di erence pry 1 jx 1 -pry 1 jx 0 =0.0876-0.0689=0.0187. On the other hand, the observed stratum-speci c risk di erence is pry 1 jx 1 z 0 pry 1 jx 0 z 0 = 0:0737 0:0637 = 0:0100 in stratum z 0 , and pry 1 jx 1 z 1 pry 1 jx 0 z 1 = 0:1092 0:0904 = 0:0188 in stratum z 1 . Thus, as noted in Kaufman et al. 2005 , there appears to bea direct causative e ect of not receiving cholestyramine on the risk of CHD in each stratum of intermediate. The bounds on the ACDE under no assumption are -0.1999, 0.3850 in stratum z 0 , and -0.7814, 0.6337 in stratum z 1 , which are relatively wide. Here, according to Kaufman et al. 2005 , it is reasonable to assume that neither cholestyramine nor absence of hyperlipidaemia may elevate risk of the outcomes, nor may cholestyramine elevate serum cholesterol, leading to 18 potential response types for consideration. In addition, the necessary test for the monotonic assumption in Section 2 shows that pry 0 jx 0 -pry 0 z 1 jx 1 =0.5823 0, and pry 1 jx 1 -pry 1 z 0 jx 0 =0.0362 0, which suggests that the monotonic assumption holds for the data. Then, according to our formulas, the bounds are 0,0.0362 in stratum z 0 , and 0,0.5823 in stratum z 1 . The upper bound in stratum z 1 can be as large as 0.5823, which is much larger than the total e ect 0.0187. Even the midpoint estimator is 0.2912, larger than 0.0187. Therefore, it may not be helpful to calculate the relative c o n tribution of the direct and indirect e ects to the total e ect, in order to validate the serum cholesterol level as a surrogate endpoint. One explanation is that there exists potential response type q 442 , which contributes the ACDEz 1 v alue but does not contribute to the total e ect.
When we restrict to 12 potential response types, again, the necessary test for no-interaction assumption holds, i.e., pry 1 jx 1 pry 1 jx 0 =0:0187 0.
The bounds on the ACDEz are 0, 0.0187 in both strata. The upper bound equals the total e ect, because the interactive p o t e n tial response type q 442 does not exist. The midpoint estimator gives an estimate 0.0094, which
indicates that there may exist a direct e ect of cholestyramine treatment o n CHD without mediating serum cholesterol. Moreover, it is noted that the boundsunder the monotonic assumption are narrower than those under no assumption, and the bounds under both monotonic and no-interaction assumptions are narrower than those under monotonic assumption. The reason is that these assumptions make some constraints on the potential response types. 6.2 Multi-categorical case Freedman et al. 1992 provided the data from the LRC-CPPT study, where the serum cholesterol values Z have 5 categories, shown in Table  4 . Based on our formulas in Section 5, we calculate the lower and upper bounds when the serum cholesterol is xed at each of the 5 categories, which are shown in Table 4 . When we compare the bounds in binary case with t h o s e i n T able 4, it is seen that with the number of categories of Z increases, the observed probabilities become smaller and the bounds become wider, which indicates that the width of the bounds is dependent on the sparcity of the observations. However, the bounds are helpful if one is interested in the ACDE under more detailed categories, which the boundsof binary case cannot provide. This paper applied the symbolicBalke-Pearl method to derive closed-form formulas for the lower and upper bounds on the ACDEs under three sets of assumptions. We also considered extensions to situations where the treatment, the intermediate and the outcome are multinomial, rather than dichotomous variables, as well as situations in which the confounding factors are partially observed, so that covariate-adjusted bounds and midpoint estimators can be obtained.
Since our approach is nonparametric and mainly based on observed information, the proposed bounds de ne a range within which the direct effect must lie. On the basis of these deterministic bounds, one can narrow the bound width substantially by introducing subject matter constraints. Therefore, these universal bounds are helpful for epidemiologists and clinical experimenters to assess the direct e ect of treatment.
Supplementary materials
Web Appendices and Tables referenced in Sections 2, 3, 5 are available under the Paper Information link at the Biometrics website http: www.tibs.org biometrics. Table 1 . De nite CHD mortality o r m yocardial infarction events Y i n t h e Table 3 . Observed conditional probabilities pry z jx s induced from Table 2 s 
